CONCLUSIONS

Thus, Enterosgel is a highly-active safe drug, which is well-tolerated by patients. Administration of Enterosgel in the complex therapy of patients with allergic diseases allows reduction of the terms of hospital treatment of patients by 10-15%, decreasing the need for antihistamine drugs, glucocorticoids, and bronchial spasmolytics, and reducing the treatment expenses by 15-20%. 

Goal of the research

Verification of clinical effectiveness and monitoring of the laboratoty values profile in patients with dermatic (atopic dermatitis, hibes) and respiratory (allergic asthma and allergic rhinitis) allergic symptoms in the period of main disease recrudescence. The influence of ENTEROSGEL taken was tested as a complementary influence in terms of the conventional basic treatment. For the purpose of making comparisons the same group of patients was monitored within the period prior to application of ENTEROSGEL.